The drug is already approved to treat a form of leukemia. John Lacey, associate director of corporate communications at Genzyme, confirmed Cohn & Wolfe had won the account.
Mike Kan, global healthcare practice leader, and Lisa Talbot, EVP and co-director of the New York healthcare practice, are leading the account for Cohn & Wolfe, said Eric Litchfield, VP of communications for the firm.
Alemtuzumab is currently enrolled in two phase three clinical trials and the company said data is expected by 2011.
In recent weeks, media outlets have speculated that Sanofi-Aventis is looking at Cambridge, MA-based Genzyme as an acquisition target.